Michele Orditura

9.2k total citations · 1 hit paper
181 papers, 6.1k citations indexed

About

Michele Orditura is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Michele Orditura has authored 181 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Oncology, 78 papers in Pulmonary and Respiratory Medicine and 35 papers in Cancer Research. Recurrent topics in Michele Orditura's work include Gastric Cancer Management and Outcomes (48 papers), Colorectal Cancer Treatments and Studies (40 papers) and Cancer Treatment and Pharmacology (27 papers). Michele Orditura is often cited by papers focused on Gastric Cancer Management and Outcomes (48 papers), Colorectal Cancer Treatments and Studies (40 papers) and Cancer Treatment and Pharmacology (27 papers). Michele Orditura collaborates with scholars based in Italy, United Kingdom and United States. Michele Orditura's co-authors include Ferdinando De Vita, Fortunato Ciardiello, Gennaro Galizia, Eva Lieto, Paolo Castellano, Giuseppe Catalano, Ciro Romano, Teresa Troiani, Floriana Morgillo and Francesca Ferraraccio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Michele Orditura

177 papers receiving 6.0k citations

Hit Papers

align trajectories

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michele Orditura Italy	44	3.4k	2.1k	1.9k	1.2k	1.0k	181	6.1k
Ferdinando De Vita Italy	43	3.4k 1.0×	2.2k 1.0×	2.0k 1.0×	1.2k 1.0×	1.0k 1.0×	207	6.0k
Masaichi Ohira Japan	46	4.0k 1.2×	2.0k 0.9×	1.6k 0.9×	1.8k 1.5×	1.4k 1.4×	417	7.0k
Gennaro Galizia Italy	43	2.8k 0.8×	1.9k 0.9×	1.2k 0.6×	1.3k 1.1×	910 0.9×	140	5.2k
Miao‐Zhen Qiu China	38	2.5k 0.8×	1.6k 0.7×	1.6k 0.9×	1.1k 0.9×	1.3k 1.2×	165	4.9k
Ping Li China	36	2.1k 0.6×	1.9k 0.9×	1.9k 1.0×	1.1k 0.9×	1.3k 1.3×	286	5.5k
Mario Scartozzi Italy	44	3.7k 1.1×	2.1k 1.0×	1.7k 0.9×	834 0.7×	1.5k 1.5×	343	6.4k
Alessandro Rizzo Italy	57	3.3k 1.0×	2.6k 1.2×	1.6k 0.9×	2.0k 1.7×	1.3k 1.2×	220	6.5k
Kun‐Huei Yeh Taiwan	38	3.4k 1.0×	2.3k 1.1×	2.2k 1.2×	1.4k 1.2×	914 0.9×	258	6.7k
Jianping Xiong China	36	2.0k 0.6×	1.6k 0.8×	2.1k 1.1×	772 0.6×	1.3k 1.3×	189	5.0k
Keishi Yamashita Japan	44	2.2k 0.7×	2.0k 1.0×	3.4k 1.8×	1.9k 1.6×	1.1k 1.1×	265	6.8k

Countries citing papers authored by Michele Orditura

Since Specialization

Citations

This map shows the geographic impact of Michele Orditura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Orditura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Orditura more than expected).

Fields of papers citing papers by Michele Orditura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Orditura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Orditura. The network helps show where Michele Orditura may publish in the future.

Co-authorship network of co-authors of Michele Orditura

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Orditura. A scholar is included among the top collaborators of Michele Orditura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Orditura. Michele Orditura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Orlando, Laura, Evaristo Maiello, Michele Orditura, et al.. (2024). Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial. The Breast. 75. 103725–103725. 1 indexed citations

2.

Facchini, Gaetano, Marco De Sio, Ferdinando De Vita, et al.. (2023). Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types. Pathology - Research and Practice. 243. 154336–154336. 4 indexed citations

3.

Facchini, Sergio, Alessia Zotta, Gaetana Messina, et al.. (2022). Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review. SHILAP Revista de lepidopterología. 15(2). 642–647. 4 indexed citations

4.

Ciaramella, Vincenza, Ferdinando Carlo Sasso, Raimondo Di Liello, et al.. (2019). Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. Journal of Experimental & Clinical Cancer Research. 38(1). 178–178. 41 indexed citations

5.

Petrillo, Angelica, F. Calabrese, Giuseppe Tirino, et al.. (2019). First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. Journal of Gastrointestinal Oncology. 10(5). 910–917. 15 indexed citations

6.

Ciaramella, Vincenza, Carminia Maria Della Corte, Giusi Barra, et al.. (2018). Acquired resistance mechanism of osimertinib targeting EGFR in human lung cancer. Annals of Oncology. 29. viii677–viii678. 1 indexed citations

7.

Laterza, Maria Maddalena, Luca Pompella, Angelica Petrillo, et al.. (2017). Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. Medical Oncology. 34(11). 186–186. 5 indexed citations

8.

Laterza, Maria Maddalena, Vincenza Ciaramella, Floriana Morgillo, et al.. (2017). Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC). Annals of Oncology. 28. v577–v577. 1 indexed citations

9.

Lieto, Eva, Gennaro Galizia, A Auricchio, et al.. (2017). Preoperative Neutrophil to Lymphocyte Ratio and Lymphocyte to Monocyte Ratio are Prognostic Factors in Gastric Cancers Undergoing Surgery. Journal of Gastrointestinal Surgery. 21(11). 1764–1774. 47 indexed citations

10.

Ventriglia, Jole, Maria Maddalena Laterza, Anna Capasso, et al.. (2016). GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab. Annals of Oncology. 27. iv22–iv22. 1 indexed citations

11.

Morgillo, Floriana, Ferdinando Carlo Sasso, Carminia Maria Della Corte, et al.. (2013). Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clinical Cancer Research. 19(13). 3508–3519. 109 indexed citations

12.

Troiani, Teresa, Erika Martinelli, Anna Capasso, et al.. (2012). Targeting EGFR in Pancreatic Cancer Treatment. Current Drug Targets. 13(6). 802–810. 115 indexed citations

13.

Vita, Ferdinando De, Francesco Giuliani, Nicola Silvestris, et al.. (2010). Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treatment Reviews. 36. S11–S15. 65 indexed citations

14.

Vita, Ferdinando De, Loredana Vecchione, Gennaro Galizia, et al.. (2009). Perspectives in Adjuvant Therapy of Gastric Cancer. Oncology. 77(Suppl. 1). 38–42. 17 indexed citations

15.

Martinelli, Erika, Raffaele De Palma, Michele Orditura, Ferdinando De Vita, & Fortunato Ciardiello. (2009). Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clinical & Experimental Immunology. 158(1). 1–9. 245 indexed citations

16.

Iovino, Francesco, Francesca Ferraraccio, Michele Orditura, et al.. (2008). Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer. Cancer Investigation. 26(3). 250–255. 23 indexed citations

17.

Orditura, Michele, Ferdinando De Vita, Giuseppe Catalano, et al.. (2002). Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis. Journal of Interferon & Cytokine Research. 22(11). 1129–1135. 68 indexed citations

18.

Vita, Ferdinando De, Ciro Romano, Michele Orditura, et al.. (2001). Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator. Journal of Interferon & Cytokine Research. 21(1). 45–52. 76 indexed citations

19.

Vita, Ferdinando De, Michele Orditura, Gennaro Galizia, et al.. (2000). Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients. CHEST Journal. 117(2). 365–373. 104 indexed citations

20.

Sarubbi, Berardo, Michele Orditura, Valentino Ducceschi, et al.. (1997). Ventricular repolarization time indexes following anthracycline treatment. Heart and Vessels. 12(6). 262–266. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact